Skip to main content
SpringerLink
Log in

What is a Kidney Worth?

  • Chapter
  • First Online:
Urothelial Malignancies of the Upper Urinary Tract

  • 410 Accesses

Abstract

Upper urinary tract urothelial carcinoma (UTUC) has traditionally been managed with radical extirpative surgery. However, conservative management with kidney-sparing endoscopic surgery is currently performed not only in those patients with imperative indications but also in those patients with low risk disease and normal, functioning contralateral kidneys, due to its similar oncological efficacy. Recent analyses relevant to our current era of cost-effective management have enabled us to understand the variety of costs associated with preserving a kidney with UTUC. Kidney-sparing surgery for UTUC offers value in delaying progression to chronic kidney disease (CKD), end-stage renal disease (ESRD), and their associated cardiovascular morbidity and mortality. By delaying the progression to CKD and ESRD, conservative endoscopic management of UTUC also effectively reduces ESRD expenditures. The kidney’s worth is ultimately furthered by the elimination of the negative impact of CKD and ESRD on a patient’s quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Rai BP, Shelley M, Coles B, Somani B, Nabi G. Surgical management for upper urinary tract transitional cell carcinoma (UUT-TCC): a systematic review. BJU Int. 2012;110(10):1426–35.

    Article  PubMed  Google Scholar 

  2. Seisen T, Colin P, Roupret M. Risk-adapted strategy for the kidney-sparing management of upper tract tumours. Nat Rev Urol. 2015;12(3):155–66.

    Article  PubMed  Google Scholar 

  3. Pak RW, Moskowitz EJ, Bagley DH. What is the cost of maintaining a kidney in upper-tract transitional-cell carcinoma? An objective analysis of cost and survival. J Endourol. 2009;23(3):341–6.

    Article  PubMed  Google Scholar 

  4. Russo P. Partial nephrectomy achieves local tumor control and prevents chronic kidney disease. Expert Rev Anticancer Ther. 2006;6(12):1745–51.

    Article  PubMed  Google Scholar 

  5. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc. 2000;75(12):1236–42.

    Article  CAS  PubMed  Google Scholar 

  6. McKiernan J, Simmons R, Katz J, Russo P. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology. 2002;59(6):816–20.

    Article  PubMed  Google Scholar 

  7. Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 2006;7(9):735–40.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Li L, Lau WL, Rhee CM, Harley K, Kovesdy CP, Sim JJ, et al. Risk of chronic kidney disease after cancer nephrectomy. Nat Rev Nephrol. 2014;10(3):135–45.

    Article  PubMed  Google Scholar 

  9. Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011;59(4):543–52.

    Article  PubMed  Google Scholar 

  10. Kaushik D, Kim SP, Childs MA, Lohse CM, Costello BA, Cheville JC, et al. Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors. Eur Urol. 2013;64(4):600–6.

    Article  PubMed  Google Scholar 

  11. Trivedi H. Cost implications of caring for chronic kidney disease: are interventions cost-effective? Adv Chronic Kidney Dis. 2010;17(3):265–70.

    Article  PubMed  Google Scholar 

  12. Kent S, Schlackow I, Lozano-Kuhne J, Reith C, Emberson J, Haynes R, et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease? BMC Nephrol. 2015;16:65.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Wyld ML, Lee CM, Zhuo X, White S, Shaw JE, Morton RL, et al. Cost to government and society of chronic kidney disease stage 1–5: a national cohort study. Intern Med J. 2015;45(7):741–7.

    Article  CAS  PubMed  Google Scholar 

  14. Miyakawa M, Yoshida O. [The quality of life in patients with bladder cancer after radical cystectomy with ileal conduit: II. Results of questionnaire surveys to compare the impact of treatments]. Nihon Gan Chiryo Gakkai shi. 1987;22(7):1296–303.

    Google Scholar 

  15. Mack D, Frick J. Quality of life in patients undergoing bacille calmette-guerin therapy for superficial bladder cancer. Br J Urol. 1996;78(3):369–71.

    Article  CAS  PubMed  Google Scholar 

  16. Hart S, Skinner EC, Meyerowitz BE, Boyd S, Lieskovsky G, Skinner DG. Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit, cutaneous or urethral kock pouch. J Urol. 1999;162(1):77–81.

    Article  CAS  PubMed  Google Scholar 

  17. Kitamura H, Miyao N, Yanase M, Masumori N, Matsukawa M, Takahashi A, et al. Quality of life in patients having an ileal conduit, continent reservoir or orthotopic neobladder after cystectomy for bladder carcinoma. Int J Urol. 1999;6(8):393–9.

    Article  CAS  PubMed  Google Scholar 

  18. Fujisawa M, Isotani S, Gotoh A, Okada H, Arakawa S, Kamidono S. Health-related quality of life with orthotopic neobladder versus ileal conduit according to the SF-36 survey. Urology. 2000;55(6):862–5.

    Article  CAS  PubMed  Google Scholar 

  19. Hardt J, Filipas D, Hohenfellner R, Egle UT. Quality of life in patients with bladder carcinoma after cystectomy: first results of a prospective study. Qual Life Res Int J Qual Life Aspects Treat Care Rehabil. 2000;9(1):1–12.

    Article  CAS  Google Scholar 

  20. McGuire MS, Grimaldi G, Grotas J, Russo P. The type of urinary diversion after radical cystectomy significantly impacts on the patient’s quality of life. Ann Surg Oncol. 2000;7(1):4–8.

    Article  CAS  PubMed  Google Scholar 

  21. Dutta SC, Chang SC, Coffey CS, Smith JA Jr, Jack G, Cookson MS. Health related quality of life assessment after radical cystectomy: comparison of ileal conduit with continent orthotopic neobladder. J Urol. 2002;168(1):164–7.

    Article  PubMed  Google Scholar 

  22. Hara I, Miyake H, Hara S, Gotoh A, Nakamura I, Okada H, et al. Health-related quality of life after radical cystectomy for bladder cancer: a comparison of ileal conduit and orthotopic bladder replacement. BJU Int. 2002;89(1):10–3.

    Article  CAS  PubMed  Google Scholar 

  23. Mansson A, Davidsson T, Hunt S, Mansson W. The quality of life in men after radical cystectomy with a continent cutaneous diversion or orthotopic bladder substitution: is there a difference? BJU Int. 2002;90(4):386–90.

    Article  CAS  PubMed  Google Scholar 

  24. Matsuda T, Aptel I, Exbrayat C, Grosclaude P. Determinants of quality of life of bladder cancer survivors five years after treatment in France. Int J Urol Official J Japanese Urol Assoc. 2003;10(8):423–9.

    Google Scholar 

  25. Yoneda T, Igawa M, Shiina H, Shigeno K, Urakami S. Postoperative morbidity, functional results and quality of life of patients following orthotopic neobladder reconstruction. Int J Urol. 2003;10(3):119–25.

    Article  PubMed  Google Scholar 

  26. Yoshimura K, Utsunomiya N, Ichioka K, Matsui Y, Terai A, Arai Y. Impact of superficial bladder cancer and transurethral resection on general health-related quality of life: an SF-36 survey. Urology. 2005;65(2):290–4.

    Article  PubMed  Google Scholar 

  27. Churchill DN, Torrance GW, Taylor DW, Barnes CC, Ludwin D, Shimizu A, et al. Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin Invest Med. 1987;10(1):14–20.

    PubMed  CAS  Google Scholar 

  28. Klinghoffer Z, Tarride JE, Novara G, Ficarra V, Kapoor A, Shayegan B, et al. Cost-utility analysis of radical nephrectomy versus partial nephrectomy in the management of small renal masses: adjusting for the burden of ensuing chronic kidney disease. Can Urol Assoc J (Journal de l’Association des urologues du Canada). 2013;7(3–4):108–13.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stamford Health Medical Group, Stamford, CT, USA

    Eric J. Moskowitz

Authors
  1. Eric J. Moskowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric J. Moskowitz .

Editor information

Editors and Affiliations

  1. Chief, Section of Endourology and Minimally Invasive Urology, Westchester Medical Health Network, Valhalla, New York, USA

    Majid Eshghi

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Moskowitz, E.J. (2018). What is a Kidney Worth?. In: Eshghi, M. (eds) Urothelial Malignancies of the Upper Urinary Tract. Springer, Cham. https://doi.org/10.1007/978-3-319-51263-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-51263-1_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-51261-7

  • Online ISBN: 978-3-319-51263-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation